专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050158747A1 CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same 审中-公开
标题翻译：可用于治疗囊性纤维化的CFTR修饰基因和表达的多肽以及用于检测和/或识别其的方法和产品
公开(公告)号：US20050158747A1
公开(公告)日：2005-07-21
申请号：US10999587
申请日：2004-11-30
申请人： Jeffrey Whitsett , Bruce Aronow , Jean Clark
发明人： Jeffrey Whitsett , Bruce Aronow , Jean Clark
IPC分类号： A01K67/00 , A61K31/353 , A61K31/4439 , C07H21/04 , C07K14/47 , C07K14/705 , C12Q1/68
CPC分类号： C07K14/4712 , A01K67/0276 , A01K2227/105 , A01K2267/0306 , A61K31/353 , A61K31/4439
摘要： The discovery that CFTR modifier genes, in particular the Kir4.2 gene, the expressed polypeptide(s), as well as genetic and polypeptide regulators thereof, can be used to treat cystic fibrosis (CF), or at least the conditions that cause CF. Methods and products for detecting and/or identifying CFTR modifier genes, their respective expressed polypeptides, the genetic regulators of such CFTR modifier genes, and the regulators of their respective expressed polypeptides are disclosed. Also disclosed are compositions and methods using these CFTR modifier genes, their respective expressed polypeptides, genetic regulators of these CFTR modifier genes, and/or CFTR modifier polypeptide regulators for the purpose of treating CF, or at least the conditions that cause CF, are disclosed.
摘要翻译：发现CFTR修饰基因，特别是Kir4.2基因，表达多肽及其遗传和多肽调节剂可用于治疗囊性纤维化（CF）或至少导致CF的条件。公开了用于检测和/或鉴定CFTR修饰基因，它们各自表达的多肽，这种CFTR修饰基因的遗传调节剂及其各自表达的多肽的调节剂的方法和产物。还公开了公开了用于治疗CF或至少导致CF的病症的这些CFTR修饰基因，它们各自表达的多肽，这些CFTR修饰基因的遗传调节剂和/或CFTR修饰多肽调节剂的组合物和方法，。

2. 发明授权

US11471274B2 Toric lens guide for use in conjunction with a toric intraocular lens so as to properly orient the toric lens in order to properly correct astigmatism 有权
公开(公告)号：US11471274B2
公开(公告)日：2022-10-18
申请号：US16812320
申请日：2020-03-08
申请人： Jeffrey Whitsett
发明人： Jeffrey Whitsett
IPC分类号： A61F2/16
摘要： A tonic lens guide comprises a substantially linear bar member and a pair of crab claw members fixedly attached to opposite ends of the linear bar member. The toric lens guide is adapted to be mounted upon an intraocular lens (IOL) which has been implanted within the capsular bag of a human eye during cataract surgery such that the substantially linear bar member is adapted to be disposed atop the central optic component of the intraocular lens (IOL) while the crab claw members effectively grasp the optica/haptic junctions of the intraocular lens (IOL). After the intraocular lens (IOL) is implanted within the capsular bag, it is rotated within the capsular bag such that the substantially linear bar member of the toric lens guide will effectively define a diametrical vector across the intraocular lens (IOL) such that the cataract surgeon can precisely orient the intraocular lens (IOL) within the capsular bag such that the patient's astigmatism is optimally corrected.

3. 发明申请

US20120053112A1 METHODS AND COMPOSITIONS RELATED TO THE REGULATION OF GOBLET CELL DIFFERENTIATION, MUCUS PRODUCTION AND MUCUS SECRETION 审中-公开
标题翻译：与细胞分化调节相关的方法和组合，MUCUS生产和MUCUS分泌
公开(公告)号：US20120053112A1
公开(公告)日：2012-03-01
申请号：US13319318
申请日：2010-05-05
申请人： Jeffrey Whitsett
发明人： Jeffrey Whitsett
IPC分类号： A61K38/00 , A61K31/7088 , C12Q1/68
CPC分类号： A61K31/4745 , C07K14/4702 , C12N15/113 , C12N2310/14 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2333/4703 , G01N2500/10 , G01N2800/122
摘要： Disclosed are methods and compositions related to the regulation of goblet cell differentiation, mucus production and mucus secretion. In some embodiments, methods for the treatment of mucus hyperproduction, methods for the treatment of pulmonary inflammation, methods of screening compounds, compositions for the treatment of mucus hyperproduction, or compositions for the treatment of pulmonary inflammation are provided.
摘要翻译：公开了与杯状细胞分化，粘液生成和粘液分泌调节相关的方法和组合。在一些实施方案中，提供了用于治疗粘液超生产的方法，用于治疗肺部炎症的方法，筛选化合物的方法，用于治疗粘液超生产的组合物或用于治疗肺部炎症的组合物。

4. 发明申请

US20050130928A1 Method for diagnosis and treatment of pulmonary disorders 有权
标题翻译：诊断和治疗肺功能障碍的方法
公开(公告)号：US20050130928A1
公开(公告)日：2005-06-16
申请号：US10988486
申请日：2004-11-12
申请人： Jeffrey Whitsett , Michael Mucenski
发明人： Jeffrey Whitsett , Michael Mucenski
IPC分类号： A01K67/027 , A61B20060101 , A61K48/00 , C07K14/475 , C12N15/85 , C12Q1/68
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0375 , A61K48/00 , C07K14/475 , C12N15/85 , C12N2830/003 , C12Q1/6897
摘要： This invention relates to the discovery that midkine modulates pulmonary vasculature development and smooth muscle cell development. Modulation of midkine activity thus alters pulmonary vasculature development and smooth muscle cell development. The invention provides methods of modulating pulmonary disorders, smooth muscle cell related disorders, and pulmonary smooth muscle cell disorders. Disorders of particular interest include, but are not limited to, asthma and pulmonary hyperplasia. Further the invention relates to the discovery that TTF1 and HIF1 -α exhibit midkine modulating activity. The invention pertains to the discovery that midkine modulates myocardin activity.
摘要翻译：本发明涉及中期因子调节肺血管发育和平滑肌细胞发育的发现。因此调节中期因子活性改变肺血管发育和平滑肌细胞发育。本发明提供调节肺病，平滑肌细胞相关病症和肺平滑肌细胞病症的方法。特别感兴趣的疾病包括但不限于哮喘和肺部增生。此外，本发明涉及TTF1和HIF1-α显示中期因子调节活性的发现。本发明涉及中期因子调节心肌素活性的发现。

5. 发明申请

US20050125851A1 Methods of diagnosis and treatment of interstitial lung disease 审中-公开
标题翻译：间质性肺病的诊断和治疗方法
公开(公告)号：US20050125851A1
公开(公告)日：2005-06-09
申请号：US10731465
申请日：2003-12-09
申请人： Jeffrey Whitsett , Stephan Glasser
发明人： Jeffrey Whitsett , Stephan Glasser
IPC分类号： A01K67/027 , A61K38/17 , G01N33/50
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K38/1709 , G01N33/5088 , A61K2300/00
摘要： The present invention provides for a method of treating pulmonary disease in a subject comprising the administration to a subject in need of such treatment a therapeutically effective amount of a formulation comprising a SP-C therapeutic. Preferably, the SP-C therapeutic is an agent selected from the group consisting of an isolated SP-C protein, an isolated nucleic acid molecule encoding a SP-C protein, a SP-C receptor-specific antibody that stimulates the activity of the receptor, or pharmaceutically acceptable composition thereof. The present invention also provides methods of producing a mouse with a targeted disruption in a surfactant protein C (SP-C) gene. The present invention also provides for a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene. The present invention further provides for a cell or cell line from a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene.
摘要翻译：本发明提供治疗受试者肺部疾病的方法，其包括向需要这种治疗的受试者施用治疗有效量的包含SP-C治疗剂的制剂。优选地，SP-C治疗剂是选自分离的SP-C蛋白，分离的编码SP-C蛋白的核酸分子，刺激受体活性的SP-C受体特异性抗体的药剂，或其药学上可接受的组合物。本发明还提供了在表面活性蛋白C（SP-C）基因中产生目标破坏的小鼠的方法。本发明还提供了通过表面活性蛋白C（SP-C）基因中靶向破坏产生的转基因小鼠。本发明还提供了通过在表面活性蛋白C（SP-C）基因中靶向破坏产生的转基因小鼠的细胞或细胞系。

6. 发明申请

US20220054313A1 NEW AND IMPROVED VITRECTOR AND METHOD FOR PERFORMING A ONE-STEP POSTERIOR VITRECTOMY USING THE SAME 有权
公开(公告)号：US20220054313A1
公开(公告)日：2022-02-24
申请号：US17519150
申请日：2021-11-04
申请人： Jeffrey Whitsett
发明人： Jeffrey Whitsett
IPC分类号： A61F9/007
摘要： A vitrector for removing material from an eye includes a hand piece, a shaft coupled at a first end to a first end of the hand piece, the shaft having a sharp second end opposite the first end of the shaft, and a cutting device positioned within the shaft and configured for removing the material from the eye. The sharp second end of the shaft is configured for piercing a pars plana of the eye and a sclera of the eye. A method for removing material from an eye includes forming a single opening through a pars plana of the eye and a sclera of the eye using a sharp point of a shaft of a vitrector, cutting the material using a cutting device incorporated within the shaft, and removing the material from the eye using the vitrector.

7. 发明申请

US20060194732A1 Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation 审中-公开
标题翻译：重组SP-A用于治疗或预防肺部感染和炎症
公开(公告)号：US20060194732A1
公开(公告)日：2006-08-31
申请号：US11413197
申请日：2006-04-28
申请人： Wolfram Steinhilber , Jeffrey Whitsett , Ann Levine , Thomas Korfhagen
发明人： Wolfram Steinhilber , Jeffrey Whitsett , Ann Levine , Thomas Korfhagen
IPC分类号： A61K38/17
CPC分类号： C07K14/785 , A61K38/00 , A61K38/1709 , Y10S514/885
摘要： Recombinant surfactant protein A and medicament compositions based thereon are useful for the prevention or treatment of pulmonary infection and inflammation.
摘要翻译：重组表面活性蛋白A及其上的药物组合物可用于预防或治疗肺部感染和炎症。

8. 发明申请

US20060078558A1 Diagnosis, prognosis and treatment of pulmonary diseases 审中-公开
标题翻译：肺部疾病的诊断，预后和治疗
公开(公告)号：US20060078558A1
公开(公告)日：2006-04-13
申请号：US10772716
申请日：2004-02-05
申请人： Jeffrey Whitsett
发明人： Jeffrey Whitsett
IPC分类号： A61K48/00 , A61K39/395
CPC分类号： A61K38/1709 , A61K2039/505 , B82Y5/00 , C07K16/18
摘要： The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. Methods are provided for supplying FoxA2 function to cells of the lung and airway, such as smooth muscle and epithelial cells, by FoxA2 gene therapy. The FoxA2 gene, a modified FoxA2 gene, or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal or may be integrated into the subjects chromosomal DNA for expression. These methods provide for administering to a subject in need of such treatment a therapeutically effective amount of a FoxA2 gene, or pharmaceutically acceptable composition thereof, for overexpressing the FoxA2 gene. Such methods of expressing the administered FoxA2 gene in the lungs and airway provide for: (1) preventing or alleving bronchial hyperresponsiveness; (2) preventing or alleving of an airway obstructive disease, e.g., bronchial hyperreactivity, airway hyperresponsiveness, asthma or chronic obstructive pulmonary disorder (“COPD”); (3) reducing the airway resistance response to inhaled natural or synthetic bronchoconstrictors or allergens or to exercise; and (4) enhancing responsiveness (relaxation) of airway tissues to β-agonists.
摘要翻译：本发明提供了保护受试者免受涉及气道阻塞性疾病如哮喘或慢性阻塞性肺病的呼吸系统疾病的方法。提供了使用基因治疗来保护受试者免受气道阻塞性疾病的方法。通过FoxA2基因治疗提供FoxA2功能供肺和气道细胞如平滑肌和上皮细胞的方法。可以将FoxA2基因，修饰的FoxA2基因或该基因的一部分引入载体中的细胞中，使得该基因保持染色体外或可以整合入受试者染色体DNA进行表达。这些方法提供了对需要这种治疗的受试者施用用于过表达FoxA2基因的治疗有效量的FoxA2基因或其药学上可接受的组合物。在肺和气道中表达施用的FoxA2基因的这种方法提供：（1）预防或反应支气管高反应性; （2）预防或调节气道阻塞性疾病，例如支气管高反应性，气道高反应性，哮喘或慢性阻塞性肺病（“COPD”）; （3）降低吸入天然或合成支气管收缩剂或过敏原或运动的气道阻力反应; 和（4）增强气道组织对β-激动剂的反应性（松弛）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式